VitroScan is presenting @EACR24 - Enriching insight in patient responses to targeted therapies

24 May 2024

Enriching insight in patient responses to targeted therapies by ex vivo tumor testing. VitroScan's Lieke Ceton and Timothy Sijsenaar will present data on patients sensitivity to targeted therapies at the @EACR24- Innovative Cancer Science Cogress.

Accumulating evidence indicates that a direct correlation between a mutated cancer gene and a response to a given therapy is too simplistic. Ex vivo tumor testing preserves the overall complexity of the tissue and cellular pathways that elicit response to treatment thus providing near patient testing. In addition, it assesses the response to targeted therapies in the context of the patients sensitivity to other drug classes in parallel.
We are looking forward to connect during the meeting. Find us at the posters find us Tuesday 11 June 2024 - EACR2024-#0808.
 

#EACR24, #targetedtherapy, #predictivetesting, #cancerresearch